James Bylund - Feb 23, 2024 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Chief Operating Officer
Signature
/s/ Kimberly Brown (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Feb 23, 2024
Transactions value $
-$777,534
Form type
4
Date filed
2/26/2024, 08:38 PM
Previous filing
Apr 4, 2023
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Options Exercise $88.7K +940 +5.35% $94.33 18.5K Feb 23, 2024 Direct
transaction RGEN Common Stock Sale -$866K -4.37K -23.63% $198.08 14.1K Feb 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Options Exercise $0 +940 +30.72% $0.00 4K Feb 23, 2024 Common Stock 940 $94.33 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 $198.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.73 to $198.46 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 2,000 shares vest and become exercisable on both 4/1/2024 and 4/1/2025.